Ticagrelor in the renal dysfunction subgroup: Subjugated or substantiated?

Circulation

Volumn 122, Issue 11, 2010, Pages 1049-1052

  Montalescot, Gilles ^a   Silvain, Johanne ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CREATININE; PLACEBO; PRASUGREL; TICAGRELOR; ADENOSINE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOT LYSIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DYSPNEA; EDITORIAL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; PRIORITY JOURNAL; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMPLICATION; HEMORRHAGE; KIDNEY DISEASE; PATHOPHYSIOLOGY; RISK FACTOR;

ACUTE CORONARY SYNDROME; ADENOSINE; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HEMORRHAGE; HUMANS; KIDNEY DISEASES; RECEPTORS, PURINERGIC P2; RISK FACTORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12;

EID: 77957272787     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.974683     Document Type: Editorial

References (18)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047. (Pubitemid 350074801)
3. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
4. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 121:357-365.
5. Goldenberg I, Subirana I, Boyko V, Vila J, Elosua R, Permanyer-Miralda G, Ferreira-González I, Benderly M, Guetta V, Behar S, Marrugat J. Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome Research and Indicators Collection Project. Arch Intern Med. 2010;170:888-895.
6. Dumaine R, Collet JP, Tanguy ML, Mansencal N, Dubois-Randé JL, Henry P, Steg PG, Michel PL, Allouch P, Cohen A, Colin P, Durand E, Montalescot G; SYCOMORE Investigators. Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). Am J Cardiol. 2004; 94:1543-1547.
7. Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K, Bhatt DL; REACH Registry Investigators. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J. 2009;158:141-148.e1.
8. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 55:1139-1146.
9. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
10. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
11. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-731.
12. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626-1636.
13. Fuster V, Farkouh ME. Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel. Circulation. 2008;118:1607-1608.
14. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122:1056-1067.
15. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ; CREDO Investigators. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155:687-693.
16. Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, Mehta SR, Yusuf S; CURE Trial Investigators. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007;14:312-318.
17. Serebruany VL, Atar D. The PLATO trial: do you believe in magic? Eur Heart J. 2010;31:764-767.
18. Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. Health Technol Assess. 2010;14(Suppl 1):31-38.